Prevalence of metabolic syndrome in psychiatric inpatients in a tertiary care centre in north India

De-addiction Centre, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
The Indian Journal of Medical Research (Impact Factor: 1.4). 01/2010; 131(1):46-52.
Source: PubMed


Metabolic syndrome (MS) is associated with major mental illnesses. It is a major predictor of mortality and morbidity. This research was undertaken to study the prevalence and correlates of MS in psychiatric inpatients in a tertiary care hospital in north India.
Consecutive adult patients with a primary psychiatric disorder admitted to the psychiatric ward during the study period (July-December 2007) were evaluated for prevalence of MS as per the criteria of the International Diabetes Federation (IDF).
Among the 90 patients included in the study, the prevalence of MS as per IDF was 37.8 per cent and it was significantly associated with the body mass index (BMI).
The present findings showed a higher prevalence of MS in psychiatric inpatients than that in the general population. Further studies on a larger sample need to be done before advising evaluation for the presence of MS in all psychiatric patients.

Download full-text


Available from: Surendra K. Mattoo, Jan 15, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the prevalence of metabolic syndrome in patients receiving clozapine. For this study, 100 patients attending the psychiatry outpatient clinic of a tertiary care hospital who were receiving clozapine for more than three months were evaluated for the presence of metabolic syndrome using the International Diabetes Federation (IDF) and modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria. Forty-six patients fulfilled IDF criteria and 47 met modified NCEP ATP-III criteria of metabolic syndrome. There was significant correlation between these two sets of criteria used to define the metabolic syndrome (Kappa value -0.821, P < 0.001). Among the individual parameters studied, increased waist circumference was the most common abnormality, followed by abnormal blood glucose levels and elevated triglyceride levels. All these abnormalities were seen in more than half (52-61%) of the patients. When the sample was divided into two groups, i.e., those with and without metabolic syndrome, patients with metabolic syndrome had significantly higher body mass index and had spent more time in school. Logistic regression analysis revealed that these two variables together explained about 19% of the variance in metabolic syndrome (adjusted r(2) = 0193; F = 12.8; P < 0.001). The findings of the present study suggest that metabolic syndrome is highly prevalent in subjects receiving clozapine.
    Indian Journal of Pharmacology 09/2011; 43(5):591-5. DOI:10.4103/0253-7613.84979 · 0.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The research on the association of metabolic syndrome (MS) and substance abuse is scanty. The present research aimed to study the prevalence and correlates of MS among the inpatients at a Drug De-addiction Centre in north India. Consecutive male subjects (N=110) admitted to a drug de-addiction centre during July to December 2009 with a primary diagnosis of alcohol or opioid dependence were evaluated for the presence of MS as per the International Diabetes Federation (IDF) criteria. The prevalence of MS was 24.6 and 29.3 per cent in alcohol and opioid dependent groups, respectively. MS showed a significant association with the age and body mass index (BMI) in the opioid dependent group. Co-morbid tobacco use was not associated with MS in either group. The prevalence of MS in our sample of alcohol and opioid dependent male inpatients was greater than the prevalence of MS in general population, however it was comparable to that reported in physical and other psychiatric disorder populations. Even though the absence of any comparative study limits the generalizability of our findings, results indicate towards a need for screening of the patients with substance dependence especially for those aged above 30 years and/or having a high BMI for MS.
    The Indian Journal of Medical Research 09/2011; 134(3):341-8. · 1.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are some reports that diabetes and metabolic syndrome (MS) are more prevalent among schizophrenia patients. However, there are very few studies in India which have estimated the prevalence of diabetes and MS in schizophrenia patients. The aim of this study was to determine the prevalence of diabetes, obesity, and MS in subjects with and without schizophrenia. This case control study comprised of "cases" i.e. subjects with schizophrenia recruited from a schizophrenia centre at Chennai and "controls" i.e. healthy age- and gender-matched subjects without psychiatric illness selected from an ongoing epidemiological study in Chennai in a 1:4 ratio of cases: Controls. Materials and Fasting plasma glucose and serum lipids were estimated for all subjects. Anthropometric measures including height, weight, and waist circumference were assessed. Diabetes and impaired fasting glucose (IFG) were defined using American Diabetes Association criteria. One-way ANOVA or student's "t" test was used to compare continuous variables and Chi-square test to compare proportion between two groups. The study group comprised of 655 subjects, 131 with schizophrenia and a control group of 524 subjects without schizophrenia. The prevalence of the diabetes, IFG, abdominal obesity and MS were significantly higher among subjects with schizophrenia compared to those without schizophrenia-diabetes (15.3% vs. 7.3%, P=0.003), IFG (31.3% vs. 8.6%, P<0.001), abdominal obesity (59.2% vs. 44.7%, P<0.001), and MS (34.4% vs. 24%, P=0.014). In subjects with schizophrenia, the prevalence of diabetes, IFG, abdominal obesity, and MS is significantly higher than in those without schizophrenia.
    Journal of Postgraduate Medicine 10/2011; 57(4):272-7. DOI:10.4103/0022-3859.90075 · 0.86 Impact Factor
Show more